Age-related macular degeneration is the leading cause of visual impairment in the elderly and treated with medication injected into the eye. Before the introduction of the drug, less than 5,000 injections were administered annually. Since then, global numbers rose to more than 90 million worldwide. However, there is a lack of an optimised approach as the injection process has mostly remained unchanged since 2004. With the Vitreoject device, we strive to disrupt the process of these injections by compromising all needed parts into one device, making it more efficient, material-saving and above all, more comfortable. Vitreoject is the only device that allows the localised sterilisation and integration of all steps into one device.